Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to cancer treatment. With a market capitalization of $4.94 billion, Celcuity is focused on developing targeted therapies to treat various solid tumors, primarily through its lead drug candidate, Gedatolisib. This drug aims to address unmet medical needs in patients with advanced or metastatic breast cancer and metastatic castration-resistant prostate cancer.

Despite being in the clinical stage, Celcuity has garnered significant attention from analysts and investors alike. The company’s stock is currently trading at $106.78, with a slight daily increase of 1.07. Over the past year, its share…